TY - JOUR AU - Balleari, Enrico AU - Corso, Lisette Del PY - 2013 TI - High-dose recombinant human erythropoietin for “low-risk” myelodysplastic patients: is more better? JF - Chinese Clinical Oncology; Vol 1, No 2 (December 01, 2012): Chinese Clinical Oncology Y2 - 2013 KW - N2 - In present issue of the Journal Azzarà and Colleagues describe a retrospective series of 133 anemic patients with low/intermediate-1 risk myelodysplastic syndromes (MDS) treated with high-dose (40,000 IU twice a week) of alpha recombinant human erythropoietin (alpha-rHuEPO) (1). UR - https://cco.amegroups.org/article/view/1353